{"pmid":32359080,"title":"Off-target ACE2 ligands: possible therapeutic option for CoVid-19?","text":["Off-target ACE2 ligands: possible therapeutic option for CoVid-19?","Br J Clin Pharmacol","Brogi, Simone","Calderone, Vincenzo","32359080"],"journal":"Br J Clin Pharmacol","authors":["Brogi, Simone","Calderone, Vincenzo"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359080","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/bcp.14343","keywords":["covid-19","sars-cov-2","betacoronavirus","human angiotensin-converting enzyme 2 (ace2)","repurposing"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495312199680,"score":9.490897,"similar":[{"pmid":32291351,"pmcid":"PMC7159901","title":"Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data.","text":["Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data.","As of today (7 April 2020), more than 81,000 people around the world have died from the coronavirus disease 19 (COVID-19) pandemic. There is no approved drug or vaccine for COVID-19, although more than 10 clinical trials have been launched to test potential drugs. In an urgent response to this pandemic, I developed a bioinformatics pipeline to identify compounds and drug candidates to potentially treat COVID-19. This pipeline is based on publicly available single-cell RNA sequencing (scRNA-seq) data and the drug perturbation database \"Library of Integrated Network-Based Cellular Signatures\" (LINCS). I developed a ranking score system that prioritizes these drugs or small molecules. The four drugs with the highest total score are didanosine, benzyl-quinazolin-4-yl-amine, camptothecin, and RO-90-7501. In conclusion, I have demonstrated the utility of bioinformatics for identifying drugs than can be repurposed for potentially treating COVID-19 patients.","mSystems","Alakwaa, Fadhl M","32291351"],"abstract":["As of today (7 April 2020), more than 81,000 people around the world have died from the coronavirus disease 19 (COVID-19) pandemic. There is no approved drug or vaccine for COVID-19, although more than 10 clinical trials have been launched to test potential drugs. In an urgent response to this pandemic, I developed a bioinformatics pipeline to identify compounds and drug candidates to potentially treat COVID-19. This pipeline is based on publicly available single-cell RNA sequencing (scRNA-seq) data and the drug perturbation database \"Library of Integrated Network-Based Cellular Signatures\" (LINCS). I developed a ranking score system that prioritizes these drugs or small molecules. The four drugs with the highest total score are didanosine, benzyl-quinazolin-4-yl-amine, camptothecin, and RO-90-7501. In conclusion, I have demonstrated the utility of bioinformatics for identifying drugs than can be repurposed for potentially treating COVID-19 patients."],"journal":"mSystems","authors":["Alakwaa, Fadhl M"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291351","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1128/mSystems.00297-20","keywords":["covid-19","drug","repurposing"],"e_drugs":["(2'-(4-aminophenyl)-(2,5'-bi-1H-benzimidazol)-5-amine)","Didanosine","Camptothecin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494428250112,"score":68.55898},{"pmid":32361588,"pmcid":"PMC7195103","title":"Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19.","text":["Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19.","Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing 'old' drugs to treat 'new' diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.","Med Hypotheses","Pindiprolu, Sai Kiran S S","Pindiprolu, Sai Harshini","32361588"],"abstract":["Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing 'old' drugs to treat 'new' diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19."],"journal":"Med Hypotheses","authors":["Pindiprolu, Sai Kiran S S","Pindiprolu, Sai Harshini"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361588","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.mehy.2020.109765","keywords":["covid-19","drug discovery","niclosamide","repurposing","sars-cov-2"],"e_drugs":["Niclosamide"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495525060608,"score":67.078835},{"pmid":32308266,"pmcid":"PMC7147498","title":"Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.","text":["Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.","Design and development of an effective drug to combat the 2019 novel coronavirus remains a challenge. Therefore, it is of interest to study the binding features of 1615 FDA approved drugs with the recently known 2019-nCoV main protease structure having high sequence homology with that from SARS-CoV. We document the binding features of top 10 drugs with the target protein. We further report that Conivaptan and Azelastine are mainly involved in hydrophobic interactions with active site residues. Both drugs can maintain close proximity to the binding pocket of main protease during simulation. However, these data need further in vitro and in vivo evaluation to repurpose these two drugs against 2019-nCoV.","Bioinformation","Odhar, Hasanain Abdulhameed","Ahjel, Salam Waheed","Albeer, Ali A Mohammed Ali","Hashim, Ahmed Fadhil","Rayshan, Ali Mahmood","Humadi, Suhad Sami","32308266"],"abstract":["Design and development of an effective drug to combat the 2019 novel coronavirus remains a challenge. Therefore, it is of interest to study the binding features of 1615 FDA approved drugs with the recently known 2019-nCoV main protease structure having high sequence homology with that from SARS-CoV. We document the binding features of top 10 drugs with the target protein. We further report that Conivaptan and Azelastine are mainly involved in hydrophobic interactions with active site residues. Both drugs can maintain close proximity to the binding pocket of main protease during simulation. However, these data need further in vitro and in vivo evaluation to repurpose these two drugs against 2019-nCoV."],"journal":"Bioinformation","authors":["Odhar, Hasanain Abdulhameed","Ahjel, Salam Waheed","Albeer, Ali A Mohammed Ali","Hashim, Ahmed Fadhil","Rayshan, Ali Mahmood","Humadi, Suhad Sami"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32308266","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.6026/97320630016236","keywords":["2019-ncov","docking","dynamics simulation","main protease","repurposing"],"e_drugs":["azelastine","conivaptan"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491199684608,"score":63.69907},{"pmid":32369435,"title":"Canine Respiratory Coronavirus: A Naturally Occurring Model of COVID-19?","text":["Canine Respiratory Coronavirus: A Naturally Occurring Model of COVID-19?","Discovered in 2003 at the Royal Veterinary College, London, canine respiratory coronavirus (CRCoV) is a betacoronavirus of dogs and major cause of canine infectious respiratory disease complex. Generally causing mild clinical signs of persistent cough and nasal discharge, the virus is highly infectious and is most prevalent in rehoming shelters worldwide where dogs are often closely housed and infections endemic. As the world grapples with the current COVID-19 pandemic, the scientific community is searching for a greater understanding of a novel virus infecting humans. Similar to other betacoronaviruses, SARS-CoV-2 appears to have crossed the species barrier, most likely from bats, clearly reinforcing the One Health concept. Veterinary pathologists are familiar with coronavirus infections in animals, and now more than ever this knowledge and understanding, based on many years of veterinary research, could provide valuable answers for our medical colleagues. Here I review the early research on CRCoV where seroprevalence, early immune response, and pathogenesis are some of the same key questions being asked by scientists globally during the current SARS-CoV-2 pandemic.","Vet Pathol","Priestnall, Simon L","32369435"],"abstract":["Discovered in 2003 at the Royal Veterinary College, London, canine respiratory coronavirus (CRCoV) is a betacoronavirus of dogs and major cause of canine infectious respiratory disease complex. Generally causing mild clinical signs of persistent cough and nasal discharge, the virus is highly infectious and is most prevalent in rehoming shelters worldwide where dogs are often closely housed and infections endemic. As the world grapples with the current COVID-19 pandemic, the scientific community is searching for a greater understanding of a novel virus infecting humans. Similar to other betacoronaviruses, SARS-CoV-2 appears to have crossed the species barrier, most likely from bats, clearly reinforcing the One Health concept. Veterinary pathologists are familiar with coronavirus infections in animals, and now more than ever this knowledge and understanding, based on many years of veterinary research, could provide valuable answers for our medical colleagues. Here I review the early research on CRCoV where seroprevalence, early immune response, and pathogenesis are some of the same key questions being asked by scientists globally during the current SARS-CoV-2 pandemic."],"journal":"Vet Pathol","authors":["Priestnall, Simon L"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369435","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1177/0300985820926485","keywords":["covid-19","sars-cov-2","animal models of human disease","betacoronavirus","canine respiratory coronavirus","dogs","emerging infectious diseases","lung","one health","pathogenesis","tracheal cultures","transmission"],"locations":["London"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1666138496158400513,"score":62.839867},{"pmid":32418327,"title":"Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.","text":["Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.","A bright spot in the SARS-CoV-2 (CoV-2) coronavirus pandemic has been the immediate mobilization of the biomedical community, working to develop treatments and vaccines for COVID-19. Rational drug design against emerging threats depends on well-established methodology, mainly utilizing X-ray crystallography, to provide accurate structure models of the macromolecular drug targets and of their complexes with candidates for drug development. In the current crisis the structural biological community has responded by presenting structure models of CoV-2 proteins and depositing them in the Protein Data Bank (PDB), usually without time embargo and before publication. Since the structures from the first-line research are produced in an accelerated mode, there is an elevated chance of mistakes and errors, with the ultimate risk of hindering, rather than speeding-up, drug development. In the present work, we have used model-validation metrics and examined the electron density maps for the deposited models of CoV-2 proteins and a sample of related proteins available in the PDB as of 1 April 2020. We present these results with the aim of helping the biomedical community establish a better-validated pool of data. The proteins are divided into groups according to their structure and function. In most cases, no major corrections were necessary. However, in several cases significant revisions in the functionally sensitive area of protein-inhibitor complexes or for bound ions justified correction, re-refinement, and eventually re-versioning in the PDB. The re-refined coordinate files and a tool for facilitating model comparisons are available at https://covid-19.bioreproducibility.org.","FEBS J","Wlodawer, Alexander","Dauter, Zbigniew","Shabalin, Ivan","Gilski, Miroslaw","Brzezinski, Dariusz","Kowiel, Marcin","Minor, Wladek","Rupp, Bernhard","Jaskolski, Mariusz","32418327"],"abstract":["A bright spot in the SARS-CoV-2 (CoV-2) coronavirus pandemic has been the immediate mobilization of the biomedical community, working to develop treatments and vaccines for COVID-19. Rational drug design against emerging threats depends on well-established methodology, mainly utilizing X-ray crystallography, to provide accurate structure models of the macromolecular drug targets and of their complexes with candidates for drug development. In the current crisis the structural biological community has responded by presenting structure models of CoV-2 proteins and depositing them in the Protein Data Bank (PDB), usually without time embargo and before publication. Since the structures from the first-line research are produced in an accelerated mode, there is an elevated chance of mistakes and errors, with the ultimate risk of hindering, rather than speeding-up, drug development. In the present work, we have used model-validation metrics and examined the electron density maps for the deposited models of CoV-2 proteins and a sample of related proteins available in the PDB as of 1 April 2020. We present these results with the aim of helping the biomedical community establish a better-validated pool of data. The proteins are divided into groups according to their structure and function. In most cases, no major corrections were necessary. However, in several cases significant revisions in the functionally sensitive area of protein-inhibitor complexes or for bound ions justified correction, re-refinement, and eventually re-versioning in the PDB. The re-refined coordinate files and a tool for facilitating model comparisons are available at https://covid-19.bioreproducibility.org."],"journal":"FEBS J","authors":["Wlodawer, Alexander","Dauter, Zbigniew","Shabalin, Ivan","Gilski, Miroslaw","Brzezinski, Dariusz","Kowiel, Marcin","Minor, Wladek","Rupp, Bernhard","Jaskolski, Mariusz"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32418327","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/febs.15366","keywords":["covid-19","protein data bank (pdb)","sars-cov-2","coronavirus","ligand validation","spike glycoprotein","structure-guided drug discovery","viral proteases"],"locations":["Ligand"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667058206854086656,"score":60.972427}]}